Breaking News

Aduro Receives Milestone From Janssen

Acceptance of IND application for ADU-741 in prostate cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aduro Biotech has received a milestone payment from Janssen Biotech for the acceptance of an investigational new drug (IND) application by the U.S. Food and Drug Administration for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. Janssen, Aduro’s license partner for ADU-741, plans to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 by the end of 2015. “We are extremely pleased with the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters